RBC Capital Thinks Xeris Pharmaceuticals’ Stock is Going to Recover


In a report issued on May 24, Daniel Busby from RBC Capital maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $10.00. The company’s shares closed last Tuesday at $3.30, close to its 52-week low of $2.45.

According to TipRanks.com, Busby is a 2-star analyst with an average return of 0.8% and a 58.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Aquestive Therapeutics.

Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $8.00, implying a 146.9% upside from current levels. In a report issued on May 14, Mizuho Securities also assigned a Buy rating to the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.94 and a one-year low of $2.45. Currently, Xeris Pharmaceuticals has an average volume of 2.38M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts